Antibody-drug conjugates (ADC) are highly potent and selective anti-tumor drugs, combining the specific targeting of mAbs with the potency of small molecule toxic payloads. Here, we employed enzymatic, site-specific conjugation to generate homogenous ADCs based on a derivative of the highly potent...
We first assessed the sensitivity of a panel of malignant T-cell lines (HH, cutaneous TCL; SUP-T1, lymphoblastic TCL; KARPAS-299, ALCL; JURKAT and HD-MAR-2, T-cell leukaemia) to CHOP, a combination of drugs reflecting the regimen used in patients.13 Escalating doses of CHOP were used...
Antimimetic drugs were administered prophylactically 30 min before the chemotherapeutic regimen was administered. During NACT, granulocyte colony-stimulating factor (G-CSF) support was required if the neutrocyte count dropped to <1.0 × 109/L. Surgery was undertaken within 1–2 weeks of NACT ...
ABCB1 encodes the P-glycoprotein – membrane transport protein –responsible for the cellular efflux of drugs, xenobiotics, cellular metabolites and anticancer agents, being crucial in response to chemotherapy. Our aim was to determine whether C1236T (rs1128503) and G2677 T/A (rs2032582) ...
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis BMJ, 360 (2018), p. k793 CrossrefView in ScopusGoogle Scholar Cited by (517) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus pla...
Anthracyclines, alone or in combination with other drugs, are among the most effective chemotherapeutic agents to treat breast cancer both in the adjuvant and neoadjuvant setting. Unfortunately, anthracycline-associated dose-dependent cardiotoxicity is a limiting factor in clinical use. Extensive efforts ...
Although both drugs reduced the number of tubules (and branches) compared to control (absence of drug), there were not significant differences between MTX and KP71.doi:10.1158/1538-7445.AM2023-4386Mitali SinghalJacobo Elies GomezSanjit Nayak...
Introduction: Anthracyclines (AC), a class of chemotherapeutic drugs, are used to treat various cancers, including breast cancer (BC). However, AC cause dose-dependent cardiac toxicity. Practice guidelines list pre-existing cardiomyopathy as a risk factor for cancer therapy-related cardiac dysfunction...
Epigenetic drugs are promising add-ons to cancer treatment; still, adverse effects concerning tumour promotion have been reported occasionally. In this in vitro study, we investigated the effect of combination treatment of decitabine with anthracycline-based chemotherapy [5-fluorouracil plus epirubicine ...
Cancer treatment during pregnancy is a growing problem especially now that women delay childbearing. Systemic treatment of these malignancies during pregnancy centers mainly on the anticancer drugs anthracyclines, widely used in treating hematological and breast cancer during pregnancy and sometimes associated...